Osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, is commonly used to treat EGFR-mutant non-small cell lung cancer. This evidence concerns the gene EGFR and non-small cell lung carcinoma.